LinkedIn: Rob Arnold
Rob holds degrees in English and Law from Cambridge University and an MBA from the Amos Tuck School of Dartmouth College. He has a Diplôme from the Sorbonne University of Paris.
His work experience began in Greece for an oil company. Following business school, he joined Strategic Decisions Group in California, where he co-developed asset securitization approaches for bank loans, including the “good bank/bad bank” structures that redefined the industry, creating new categories of securities and freeing up billions of dollars of capital for more productive use. After seven years in San Francisco, Rob started SDG’s London office with others. He co-developed a solution to pharma R&D allocation, about which he co-authored an HBR article, and which became the industry gold standard, transforming how pharma thought about value and creating the environment to resource many of today’s best-selling drugs.
Rob served as CEO of SDG for six years, ultimately presiding over its sale to IMS, where he became global VP of strategy consulting, growing the business globally to $120 million and advising IMS’s board on strategy, while working with many pharma CEOs. Following PE’s acquisition of IMS, Rob moved to Singapore, where he jointly founded a life science consulting and services firm that EVERSANA ultimately acquired. After twelve years building out a multi-country Asian footprint for the business, he returned to the US.
Rob has spoken, taught, and published extensively, promoting DQ to clients as diverse as the UK Police, government wealth funds, upstream oil and gas companies, and ecotechnology companies. He has guest lectured at Tuck, INSEAD, LBS, and the
London School of Economics, among others, and keynoted pharma industry global gatherings.